Predictive Factors and Prognostic Value of Pathologic Complete Response of Internal Mammary Lymph Nodes in Breast Cancer After Neoadjuvant Chemotherapy
10.3971/j.issn.1000-8578.2022.22.0285
- VernacularTitle:乳腺癌新辅助化疗后同侧内乳区淋巴结病理完全缓解的预测因素及预后价值
- Author:
Weifang ZHANG
1
;
Jinzhao LIU
;
Xiangmei ZHANG
;
Shuo ZHANG
;
Xiangmin MA
;
Yunjiang LIU
Author Information
1. Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011. China
- Publication Type:Research Article
- Keywords:
Breast cancer;
Neoadjuvant chemotherapy;
Internal mammary lymph node;
Pathological complete response
- From:
Cancer Research on Prevention and Treatment
2022;49(12):1240-1244
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the prognostic factors of the pathological complete response of internal mammary lymph node (ipCR) after neoadjuvant chemotherapy and its effect on breast cancer prognosis. Methods We retrospectively analyzed the clinical data of 70 patients with primary breast cancer with internal mammary lymph node metastasis who received neoadjuvant chemotherapy. Patients were divided into the ipCR group and non-ipCR group based on their postoperative pathology. χ2 test, Fisher, and Logistic regression were used for univariate and multivariate analysis. Meanwhile, the Kaplan-Meier curve and Cox regression were used for prognostic analysis. Results Of 70 patients, 31 obtained ipCR (44.3%). Univariate analysis showed that the expression levels of apCR, HR, and HER2 status were related to ipCR (P < 0.05). Multivariate analysis showed that age, apCR, and HER2 status were independent predictors of ipCR (P < 0.05). The average DFS of ipCR group was better than non-ipCR group (96.0 vs. 67.1 months, P < 0.05). The risk of recurrence and metastasis was 87% lower in the ipCR group than in the non-ipCR group (HR=0.13, 95%CI: 0.04-0.44, P < 0.01). ipCR, Ki67 expression level, and breast pCR (bpCR) were independent factors affecting patients' prognosis. Conclusion There is a correlation between clinico pathological factors and ipCR after neoadjuvant chemotherapy. ipCR can be used to predict the prognosis of patients with internal mammary lymph node metastasis.
